Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein

被引：59
|
作者：
Vishnuvardhan, D [1 ]
von Moltke, LL
Richert, C
Greenblatt, DJ
机构：
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Univ Konstanz, Dept Chem, D-7750 Constance, Germany
来源：
AIDS | 2003年 / 17卷 / 07期
关键词：
D O I：
10.1097/00002030-200305020-00023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The effect of lopinavir on P-glycoprotein-mediated rhodamine 123 efflux was studied in Caco-2 monolayer cells. Lopinavir is a potent inhibitor of Rh123 efflux in Caco-2 monolayers (IC50 1.7 muM). Chronic lopinavir exposure (72 h) in LS 180V cells reduced the content of intracellular Rh123 by approximately 50%, indicating increased efflux activity. In LS 180V cells, lopinavir induced P-glycoprotein immunoreactive protein (up to threefold) and messenger RNA levels in a concentration-dependent fashion.
引用
收藏
页码：1092 / 1094
页数：3
相关论文
共 50 条
  • [1] Acute Exposure to Doxorubicin Results in Increased Cardiac P-glycoprotein Expression
    Budde, Thomas
    Haney, Jeanette
    Bien, Sandra
    Schwebe, Matthias
    Riad, Alexander
    Tschoepe, Carsten
    Staudt, Alexander
    Jedlitschky, Gabriele
    Felix, Stephan B.
    Kroemer, Heyo K.
    Grube, Markus
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (09) : 3951 - 3958
  • [2] P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception
    Brown, Sarah M.
    Campbell, Scott D.
    Crafford, Amanda
    Regina, Karen J.
    Holtzman, Michael J.
    Kharasch, Evan D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 343 (01): : 53 - 61
  • [3] P-GLYCOPROTEIN AND PHARMACOKINETICS
    LEVEQUE, D
    JEHL, F
    ANTICANCER RESEARCH, 1995, 15 (02) : 331 - 336
  • [4] Structure of P-glycoprotein
    Chang, Geoffrey
    Ward, Andrew
    Caya, Alexandra
    Aller, Stephen G.
    Yu, Jodie
    Weng, Yue
    Chittaboina, Srinivas
    Harrell, Patina M.
    Zhuo, Rupeng
    Trinh, Yenphuong T.
    Zhang, Qinghai
    Urbatsch, Ina L.
    DRUG METABOLISM REVIEWS, 2010, 42 : 6 - 7
  • [5] Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors
    Gherbovet, Olga
    Alvarez, Maria Concepcion Garcia
    Bignon, Jerome
    Roussi, Fanny
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (23) : 10774 - 10780
  • [6] Saint John's wort:: An in vitro analysis of P-glycoprotein induction due to extended exposure
    Perloff, MD
    von Moltke, LL
    Störmer, E
    Shader, RI
    Greenblatt, DJ
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (08) : 1601 - 1608
  • [7] Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs
    Kono, Yusuke
    Kawahara, Iichiro
    Shinozaki, Kohei
    Nomura, Ikuo
    Marutani, Honoka
    Yamamoto, Akira
    Fujita, Takuya
    PHARMACEUTICS, 2021, 13 (03)
  • [8] The cannabinoid cannabidiol inhibits P-glycoprotein activity.
    Zhu, HJ
    Wang, JS
    Markowitz, JS
    Donovan, JL
    Gibson, BB
    Gefroh, HA
    DeVane, LC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P75 - P75
  • [9] Loperamide inhibits P-glycoprotein mediated transport of irinotecan
    Tobin, PJ
    Allen, J
    Rivory, LP
    DRUG METABOLISM REVIEWS, 2003, 35 : 155 - 155
  • [10] Acetaminophen Inhibits Intestinal P-Glycoprotein Transport Activity
    Novak, Analia
    Delli Carpini, Griselda
    Laura Ruiz, Maria
    Luquita, Marcelo G.
    Rubio, Modesto C.
    Mottino, Aldo D.
    Ghanem, Carolina I.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (10) : 3830 - 3837
12345